AbbVie Inc (ABBV)vsApplovin Corp (APP)
ABBV
AbbVie Inc
$207.18
+0.96%
HEALTHCARE · Cap: $362.83B
APP
Applovin Corp
$435.91
-5.02%
COMMUNICATION SERVICES · Cap: $155.10B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1016% more annual revenue ($61.16B vs $5.48B). APP leads profitability with a 60.8% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.49. APP earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Buy63
out of 100
Grade: C+
APP
Strong Buy77
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1190.8%
Fair Value
$16.05
Current Price
$207.18
$191.13 premium
Margin of Safety
+10.4%
Fair Value
$470.34
Current Price
$435.91
$34.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Keeps 61 of every $100 in revenue as profit
Strong operational efficiency at 76.9%
Revenue surging 65.9% year-over-year
Earnings expanding 84.7% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
ROE of 2.1% — below average capital efficiency
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 69.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : APP
The strongest argument for APP centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 60.8% and operating margin at 76.9%. Revenue growth of 65.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.
Bear Case : APP
The primary concerns for APP are Return on Equity, Debt/Equity, P/E Ratio. A P/E of 45.7x leaves little room for execution misses. Debt-to-equity of 1.66 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while APP is a growth play — different risk/reward profiles.
APP carries more volatility with a beta of 2.50 — expect wider price swings.
APP is growing revenue faster at 65.9% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
APP scores higher overall (77/100 vs 63/100), backed by strong 60.8% margins and 65.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Applovin Corp
COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA
AppLovin Corporation is committed to creating a software-based platform for mobile application developers to improve the marketing and monetization of their applications globally. The company is headquartered in Palo Alto, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?